Aligos Therapeutics Inc. (ALGS): Price and Financial Metrics


Aligos Therapeutics Inc. (ALGS): $1.13

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ALGS to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

ALGS Stock Price Chart Interactive Chart >

Price chart for ALGS

ALGS Price/Volume Stats

Current price $1.13 52-week high $2.46
Prev. close $1.13 52-week low $0.84
Day low $1.09 Volume 34,500
Day high $1.16 Avg. volume 401,263
50-day MA $1.61 Dividend yield N/A
200-day MA $1.29 Market Cap 48.52M

Aligos Therapeutics Inc. (ALGS) Company Bio


Aligos Therapeutics, Inc. develops targeted, curative therapies for hepatologic diseases and viral infections. It engages in building a pipeline of drug candidates which targets multiple clinically validated mechanisms of action and are designed to achieve functional cure for CHB and become transformative treatment options for COVID-19 and NASH. The company was founded by Lucinda Quan and Lawrence M. Blatt on February 05, 2018 and is headquartered in South San Francisco, CA.


ALGS Latest News Stream


Event/Time News Detail
Loading, please wait...

ALGS Latest Social Stream


Loading social stream, please wait...

View Full ALGS Social Stream

Latest ALGS News From Around the Web

Below are the latest news stories about ALIGOS THERAPEUTICS INC that investors may wish to consider to help them evaluate ALGS as an investment opportunity.

Aligos Therapeutics, Inc. (ALGS) Reports Q4 Loss, Tops Revenue Estimates

Aligos Therapeutics, Inc. (ALGS) delivered earnings and revenue surprises of -4.08% and 26.32%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | March 9, 2023

Aligos Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2022 Financial Results

SOUTH SAN FRANCISCO, Calif., March 09, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and financial results for the fourth quarter and full year 2022. "Last year was very productive for our team,” said Lawrence Blatt, PhD, MBA, Chairman & CEO of Aligos. “We made great progress advancing our NASH

Yahoo | March 9, 2023

Aligos Therapeutics to Announce Fourth Quarter Results March 9, 2023

SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, the “Company”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in nonalcoholic steatohepatitis (NASH) and viral diseases, today announced that it will report the Company’s fourth quarter 2022 financial results on Thursday, March 9, 2023 after the close of the U.S. financial markets. About AligosAligos Therapeutics, I

Yahoo | February 28, 2023

Aligos Therapeutics Presents Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver

SOUTH SAN FRANCISCO, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in NASH and viral diseases, today announced that the company is delivering several oral and poster presentations at the 32nd Conference of the Asian Pacific Association for the Study of the Liver (APASL), being held Feb 15 – 19 in Taipei, Taiwan at the Taipei International Conven

Yahoo | February 16, 2023

Aligos Therapeutics to Present Program Updates at the 32nd Conference of the Asian Pacific Association for the Study of the Liver

SOUTH SAN FRANCISCO, Calif., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in NASH and viral diseases, today announced that the company will deliver several oral and poster presentations at the 32nd Conference of the Asian Pacific Association for the Study of the Liver (APASL), being held Feb 15 – 19 in Taipei, Taiwan at the Taipei International Convent

Yahoo | February 14, 2023

Read More 'ALGS' Stories Here

ALGS Price Returns

1-mo -31.10%
3-mo 24.23%
6-mo 13.00%
1-year -50.44%
3-year N/A
5-year N/A
YTD 18.59%
2022 -91.97%
2021 -57.07%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7187 seconds.